key: cord-0703708-yqd9fdj0 authors: Fenoglio, Daniela; Dentone, Chiara; Parodi, Alessia; Di Biagio, Antonio; Bozzano, Federica; Vena, Antonio; Fabbi, Marina; Ferrera, Francesca; Altosole, Tiziana; Bruzzone, Bianca; Giacomini, Mauro; Pelosi, Paolo; De Maria, Andrea; Bassetti, Matteo; De Palma, Raffaele; Filaci, Gilberto title: Characterization of T lymphocytes in severe COVID‐19 patients date: 2021-05-03 journal: J Med Virol DOI: 10.1002/jmv.27037 sha: 1a5d4d29dd0a01ae69783203415fda54b867e149 doc_id: 703708 cord_uid: yqd9fdj0 In this observational study, 13 patients with severe COVID‐19 and 10 healthy controls were enrolled. The data concerning the analysis of circulating T cells show that, in severe COVID‐19 patients, the expansion of these cell compartments is prone to induce antibody response, inflammation (CCR4+ and CCR6+ TFH) and regulation (CD8+ Treg). This pathogenic mechanism could lead us to envision a possible new form of biological target therapy. The coronavirus disease caused by SARS-CoV-2 is determining a severe pandemic, indicating that immunity induced by other coronaviruses commonly circulating in the population 1,2 does not cover and protect a great part of the world population. The SARS-CoV-2 infection can lead to different clinical pictures (from asymptomatic/pauci-symptomatic infection to moderate/severe forms of the disease), suggesting that the clinical picture of the infection might strictly depend on the outcome of the SARS-CoV-2immune system interaction in the patient. 3 Therefore, it is conceivable that patients with the worst forms of disease could have an immunological imbalance due to hampered virus eradication and overwhelming inflammatory response. 4 To investigate the immunological dynamics in SARS-CoV-2infected patients with severe disease, 5 we performed a study on peripheral T lymphocytes from patients with severe COVID-19 in comparison to T cells from healthy controls. The study was carried out in compliance with the Helsinki Declaration and approved by the Ethical Committee of the San Martino Hospital in Genoa (N. CER Liguria 114/2020-ID 10420). All enrolled patients and subjects provided informed consent. Immunofluorescence analyses were performed on 100 µl of peripheral and on 1 × 10 6 cells peripheral blood mononuclear cells (PBMC) purified from heparinized blood samples by centrifugation on Ficoll-Hypaque gradient incubating with specific fluorochrome-conjugated monoclonal antibodies (all purchased from BD Biosciences), as indicated in Table S1 . To perform FoxP3 staining, the PBMC were incubated with Aqua dead (Molecular Probes, Thermo Fisher Scientific) for 15 min at room temperature to exclude dead cells before proceeding with surface staining. To perform intranuclear staining, As regards the analysis strategy to follow the maturation of the CD4+ and CD8+ T populations, T-cell differentiation has been delineated using a set of canonical markers, that is, CD45RA, CCR7, CD28, and CD95. 6 Briefly, the differential expression of these markers allows the identification of six subsets in the human peripheral blood: naive (T N ), stem cell memory (T SCM ), central memory (T CM ), transitional memory (T TM ), effector memory (T EM ), and terminal effector (T TE ), as shown in Figure S1 . Moreover, to complete the study, we analyzed the activation markers on CD4+ and CD8+ T cells as an expression of CD38+ , DR+, and CD38+DR+. In particular, we considered the following specific phenotypic pat- The statistically significant differences (p < 0.05) between means of immunological parameters from patients and healthy subjects were analyzed by Mann-Whitney t test for nonparametric values. Calculations were performed by GraphPad Prism v.5 software (GraphPad Software). Peripheral blood was collected from 13 patients affected by severe COVID-19 (Table S1 ) and from 10 healthy subjects. We focused on phenotypic features of cell maturation, activation, and functional commitment. First, we analyzed CD3+, CD4+, Of note, the study of T-cell activation, through the analysis of expression of activation markers, such as CD38 and DR antigens, showed that both CD4+ and CD8+ T-cell subsets of SARS-CoV-2infected patients were highly activated as expressing CD38 and DR antigens at a remarkably higher frequency than those of healthy subjects ( Figure 1N-S) . To further characterize the immune response of these patients, we studied the T-cell functional commitment. Due to the technical limitations working with biological samples from SARS-CoV-2infected patients, related to the need to avoid any manipulation process potentially leading to the virus spreading in the environment, we inferred functional information analyzing phenotypical patterns strictly associated with specific functional commitments, as detailed in Table S1 . 7 In Figure 2A the analysis strategy of Th subsets in peripheral blood is indicated. Figure 2B ,a-d shows that COVID-19 patients had comparable TFH frequency in comparison to healthy subjects, but with a different functional commitment of these cells between patients and controls. We observed a reduction of both Th1 and Th17-1 T-cell subsets ( Figure 2B,e,h) . No significant differences concerning the frequencies of Th2, Th17, Th9, and Th22 T cells were detected between patients and controls ( Figure 2B,f,g,i,j) . We also studied the regulatory T cells. In particular, we analyzed the circulating frequencies of CD4+CD25+Foxp3+ and CD8+CD28−CD127loCD39+ regulatory T lymphocyte (Treg) subsets. The interest for the latter one originated from our recent finding of its expansion in the circulation of HIV-infected patients. 12 The frequency of CD4+CD25+Foxp3+ Treg was comparable in the two groups, while we observed a significantly higher frequency of CD8+CD28−CD127loCD39+ Treg in the circulation of patients ( Figure 2B,l-m) . In fact, SARS-CoV-2-infected patients had decreased frequency of CXCR3+ Th1-oriented TFH and increased frequencies of both CCR4+ Th2-oriented and CCR6+ Th17-oriented TFH. 8, 9 These findings, together with the reduction of Th1 and Th17-1 T-cell subsets, 10 We found no differences between elderly patients (defined as ≥80 years) and patients <80 years old concerning the immunological parameters analyzed, as reported recently in the literature. 18, 19 These results could derive from the small number of patients analyzed and/or from the group of patients enrolled in the study with severe COVID-19. Our data show a robust immune response in patients with severe COVID-19 characterized by relative expansion of T-cell subsets typical of persistent viral infection and prone to sustain inflammation (Th2-and Th17-oriented TFH) as well as T-cell subtypes devoted to regulation (CD8+ Treg), and by relative reduction of Th1 cells, which are those associated with eradication of a viral infection. This pathogenic mechanism could lead us to envision a possible new form of biological target therapy. The study was supported by a generous donation from Mediolanum Farmaceutici S.p.A. SARS and other coronaviruses as causes of pneumonia Hosts and sources of endemic human coronaviruses COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal The who's who of T-cell differentiation: human memory T-cell subsets OMIP-017: human CD4 + helper T-cell subsets including follicular helper cells Phenotype and functions of memory Tfh cells in human blood Induction of Th1-biased T follicular helper (Tfh) cells in lymphoid tissues during chronic Simian immunodeficiency virus infection defines functionally distinct germinal center Tfh cells Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells Overcoming CD4 Th1 cell fate restrictions to sustain antiviral CD8 T cells and control persistent virus infection Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Comprehensive mapping of immune perturbations associated with severe COVID-19 Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells Immune parameters and COVID-19 infection-associations with clinical severity and disease prognosis CD8+CD28-CD127loCD39+ regulatory T-cell expansion: a new possible pathogenic mechanism for HIV infection? Immunesenescence: a predisposing risk factor for the development of COVID-19? Impaired cytotoxic CD8 + T cell response in elderly COVID-19 patients Characterization of T lymphocytes in severe COVID-19 patients The authors declare no conflict of interests. All authors contributed to the writing of the manuscript. The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request. http://orcid.org/0000-0002-9096-5812Antonio Di Biagio https://orcid.org/0000-0003-1436-5089Andrea De Maria http://orcid.org/0000-0001-5782-333XMatteo Bassetti https://orcid.org/0000-0002-0145-9740